[Comment] The triumph of HIV treatment: another new antiretroviral

Since the approval of the first integrase strand inhibitor (INSTI) raltegravir for the treatment of HIV 10 years ago, INSTIs have become agents of choice in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) in many international guidelines.1,2 This was driven by the sound real-world experience of this antiretroviral class, especially following the introduction of the most recently licensed INSTI, dolutegravir.

Source: LANCET - August 31, 2017 Category: General Medicine Authors: Marta Boffito, Francois Venter Tags: Comment Source Type: research